CStone announces acceptance of its first New Drug Application in mainland China by the National Medical Products Administration, for the first-in-class precision therapy avapritinib in two gastrointestinal stromal tumor indications
- Written by ACN Newswire
HONG KONG, Apr 23, 2020 - (ACN Newswire) - CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) of the precision therapy avapritinib for two indications, one for the treatment of adults with unresectable or metastatic...